Amneal Reports Q2 2025 Earnings with Revenue Growth
Amneal (AMRX) reported second-quarter revenue of $720 million and adjusted EBITDA of $184 million for the quarter ending August 5, 2025. The company raised its full-year guidance due to consistent performance over six years and highlighted several growth drivers including new product launches such as CREXONT and Brekiya autoinjector.
Tickers: $AMRX
Topics: biosimilars branded drugs generics GLP-1 pharmaceuticals